PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.
Helen works as an Investment manager at Almi Invest South. She focuses on Life Science and is responsible for the entire investment process at Almi. Currently, she is the investment manager of four of Almi Invest South’s portfolio companies and a board member of two companies.
Helen has a PhD in Tumor Immunology and began her career as a translational cancer researcher. She has for several years worked with project management and network platforms for life science stakeholders from academia, industry and healthcare. Before joining Almi Invest, Helen was a Senior project manager at the Danish-Swedish cluster organization Medicon Valley Alliance and before that a Senior project manager at the science park Medicon Village.
PharmNovo is welcoming Helen to the team!
Patent granted in China
We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in China. PharmNovo AB is currently entering into regulatory toxicology studies with PN6047 – an exciting phase in the development of this biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins. In preclinical testing, our candidate effectively reduces neuropathic pain without any of the unwanted side effects of conventional opioids.Read more →
22 MSEK new funding
PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.Read more →
As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.Read more →
New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.Read more →